IL-1 switches on tumors

Iinterleukin-1 (IL-1) is a proinflammatory cytokine with various immune, degradative, and growth promoting roles. There are two IL-1 agonistic proteins — IL-1β and IL-1α — and one antagonistic protein, the IL-1 receptor antagonist IL-1Ra — commercially produced as anakinra and used in the treatment of rheumatoid arthritis. However, the roles of endogenous IL-1 in mediating in vivo tumor growth and angiogenesis have been unclear. In the February 18 Proceedings of the National Academy of Sciences, Elena Voronov and colleagues at the Ben-Gurion University of the Negev, Beer-Sheva, Israel, show that microenvironmental IL-1β and, to a lesser extent, IL-1α are required for in vivo angiogenesis and invasiveness for certain tumor cells (PNAS, DOI:10.1073/pnas.0437939100, February 18, 2003).

Voronov et al. used IL-1β and IL-1α knockout mice. They observed that various types of tumor cell — including B16 melanoma cells — failed to develop into local tumors...